Pressure ulcer
Chapter 12:Diseases of the skin and subcutaneous tissue
ICD-10 L89 is a used to indicate a diagnosis of pressure ulcer.
Pressure ulcers, also known as decubitus ulcers or bedsores, are localized injuries to the skin and/or underlying tissue that occur as a result of prolonged pressure, often in patients with limited mobility. These ulcers typically develop over bony prominences such as the sacrum, heels, and elbows. Clinically, pressure ulcers are classified into four stages based on the depth of tissue damage: Stage I (non-blanchable erythema), Stage II (partial thickness skin loss), Stage III (full thickness skin loss), and Stage IV (full thickness tissue loss with exposed bone, tendon, or muscle). The progression of pressure ulcers can be influenced by factors such as moisture, friction, and shear forces, as well as the patient's overall health status, including nutritional deficiencies and comorbidities. Diagnostic considerations include a thorough clinical assessment, including the ulcer's stage, size, and characteristics, as well as patient history and risk factors. Early identification and intervention are crucial to prevent complications such as infection and sepsis.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L89 covers various stages of pressure ulcers, including Stage I, II, III, and IV, as well as unstageable pressure ulcers. Each stage has specific diagnostic criteria based on the depth of tissue damage and the presence of necrotic tissue.
L89 should be used when documenting pressure ulcers specifically. If the condition is not related to pressure ulcers, other codes such as L90 may be more appropriate. Accurate staging is essential for proper code selection.
Documentation should include the ulcer's location, stage, size, and any associated symptoms. Additionally, the patient's risk factors, treatment plan, and response to treatment should be clearly documented to support the use of L89.
